We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Aridis Pharmaceuticals

News List

Aridis Pharmaceuticals COVID mAb AR-712 Neutralizes SARS-CoV-2 Delta Variant firstwordpharma
July 13, 2021
Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS) announced today that its COVID-19 mAb cocktail AR-712 binds and neutralizes the Delta variant virus SARS-CoV-2 at a highly effective level (~20ng/mL).
Aridis Pharmaceuticals Receives Orphan Drug Designation for AR-501 americanpharmaceuticalreview
June 28, 2019
Aridis Pharmaceuticals announced the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to AR-501, the Company's inhaled formulation of gallium citrate for treatment of lung infection in patients with cystic fibrosis.